Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gray Sheet

Executive Summary

Secondary offering of 3 mil. shares is planned at an estimated price of $14.50 per share. The Hayward, California firm, which produces the Cholestech L(D(X point-of-care analyte diagnostic system for multiple blood-detected diseases and disorders, plans to use anticipated net proceeds of approximately $40.4 mil. for expansion of manufacturing capacity in fiscal 1999, R&D expenses, "expansion of sales and marketing capabilities," other capital expenditures and working capital, and SG&A, the SEC filing states. Cholestech recorded sales of $21.7 mil. for the fiscal year ended March 27, 1998 (up 68%); earnings increased to roughly $2 mil. in its first year of profitability. Lead underwriter Prudential Securities and co-managers Vector Securities International and Everen Securities hold an over-allotment option for 450,000 shares, which could bring net proceeds to $46.5 mil

You may also be interested in...

COVID-19 Vaccine 'Brexit Bonus' A Myth

The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.

Warning Letter Close-Outs – November 2020

The US Food and Drug Administration posted two device-related closeout letters in November.

Jazz And PharmaMar’s Zepzelca Hits Buffers In ATLANTIS Study

Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts